Gilead misses key goal in NASH liver disease trial, shares sink

88

Gilead Sciences Inc said on Monday that a late-stage study of a key experimental drug aimed at treating NASH, a progressive fatty liver disease, failed to meet its main goal, sending the company’s shares down 4.6 percent in after-hours trading.

http://feeds.reuters.com/~r/reuters/healthNews/~3/6odcP6a7xPw/gilead-misses-key-goal-in-nash-liver-disease-trial-shares-sink-idUSKCN1Q02HU

- Advertisement -